$AVTR earnings report

Avantor® Reports Third Quarter 2026 Results. AlphAI read Avantor's Third Quarter 2026 filing as solid. 2 quarters are on record below.

Third Quarter 2026

AlphAI · Earnings readAVTR · Third Quarter 2026 · ended September 30, 2026

Avantor® Reports Third Quarter 2026 Results

✓Solid quarter

Third-quarter net sales increased 4.6% and organic net sales increased 5.2%, both segments posted organic growth, and fiscal 2026 organic revenue growth, adjusted EPS and free cash flow guidance were raised. Adjusted EBITDA, adjusted operating income, adjusted net income and free cash flow were below their prior-year-period amounts, while VWR Distribution & Services adjusted operating income margin declined.

Revenue
$1.70B
4.6% y/y
VWR Distribution & Services, three months ended September 30, 2026
$1.23B
5.0% y/y
EPS · GAAP
$0.30
Fiscal 2026 guidance (as of October 28, 2026) outlook
+0.75% to +1.25% organic revenue growth

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net sales, three months ended September 30, 2026GAAP$1.70B–4.6%
Organic net sales growth, three months ended September 30, 2026non-GAAP5.2%–5.2%
Foreign currency translation impact on net sales, three months ended September 30, 2026othernegative impact of 0.6%––
Cost of sales, three months ended September 30, 2026GAAP$1.16B––
Gross profit, three months ended September 30, 2026GAAP$534.8M––
Selling, general and administrative expenses, three months ended September 30, 2026GAAP$395.3M––
Operating income, three months ended September 30, 2026GAAP$139.5M––
Operating income margin, three months ended September 30, 2026GAAP8.2%––
Adjusted Operating Income, three months ended September 30, 2026non-GAAP$227.6M––
Adjusted Operating Income margin, three months ended September 30, 2026non-GAAP13.4%––
Interest expense, net, three months ended September 30, 2026GAAP−$39.9M––
Loss on extinguishment of debt, three months ended September 30, 2026GAAP−$800K––
Other expense, net, three months ended September 30, 2026GAAP−$800K––
Income before income taxes, three months ended September 30, 2026GAAP$98M––
Income tax benefit, three months ended September 30, 2026GAAP$105.4M––
Net income, three months ended September 30, 2026GAAP$203.4M––
Net income margin, three months ended September 30, 2026GAAP12.0%––
Adjusted net income, three months ended September 30, 2026non-GAAP$146.4M––
Diluted earnings per share, three months ended September 30, 2026GAAP$0.30––
Basic earnings per share, three months ended September 30, 2026GAAP$0.30––
Adjusted EPS, three months ended September 30, 2026non-GAAP$0.22––
Adjusted EBITDA, three months ended September 30, 2026non-GAAP$256.9M––
Adjusted EBITDA margin, three months ended September 30, 2026non-GAAP15.1%––
Weighted average diluted shares outstanding, three months ended September 30, 2026GAAP680.9M––
Net sales, nine months ended September 30, 2026GAAP$4.97B–1.7%
Organic net sales growth, nine months ended September 30, 2026non-GAAP0.3%–0.3%
Gross profit, nine months ended September 30, 2026GAAP$1.57B––
Operating income, nine months ended September 30, 2026GAAP$360.8M––
Net income, nine months ended September 30, 2026GAAP$284.8M––
Diluted earnings per share, nine months ended September 30, 2026GAAP$0.42––
Adjusted EPS, nine months ended September 30, 2026non-GAAP$0.60––
Adjusted EBITDA, nine months ended September 30, 2026non-GAAP$730.6M––
Adjusted EBITDA margin, nine months ended September 30, 2026non-GAAP14.7%––
Adjusted Operating Income, nine months ended September 30, 2026non-GAAP$643.3M––
Adjusted Operating Income margin, nine months ended September 30, 2026non-GAAP12.9%––

Segments

SegmentRevenueq/qy/y
VWR Distribution & Services, three months ended September 30, 2026Foreign currency translation had a negative impact of 0.8%, resulting in a sales increase of 5.8% on an organic basis. Adjusted Operating Income margin declined versus the prior year due to unfavorable product mix and higher SG&A expenses, partially offset by higher sales volume.$1.23B–5.0%
Bioscience & Medtech Products, three months ended September 30, 2026Foreign currency translation had a negative impact of 0.1%, resulting in a 3.6% sales increase on an organic basis. Adjusted Operating Income margin was flat versus the prior year due to higher sales volume and commercial excellence, partially offset by higher SG&A expenses.$464.5M–3.5%
VWR Distribution & Services, nine months ended September 30, 2026Foreign currency impact was 1.6% and organic net sales growth was 0.9%.$3.62B–2.5%
Bioscience & Medtech Products, nine months ended September 30, 2026Foreign currency impact was 1.1% and organic net sales growth was (1.4)%.$1.35B–(0.3)%

Fiscal 2026 guidance (as of October 28, 2026) outlook

  • Revenue+0.75% to +1.25% organic revenue growth
  • Tax rateAdjusted effective tax rate between 22.0% and 22.5%
  • NoteAdjusted EBITDA margin: 14.8% to 15.3%
  • NoteAdjusted EPS: $0.81 to $0.83
  • NoteFree cash flow: $525M to $550M
  • NoteReported revenue growth range is +1.5% to +2.0%, reflecting +0.75% foreign exchange tailwind
  • NoteBlended EUR/USD exchange rate of 1.15
  • NoteNet interest expense is expected to decline modestly when compared to Fiscal 2025
  • NoteFully diluted share count of 679M shares
  • NoteFree cash flow excludes cash restructuring costs

Capital returns

  • Shares repurchased to satisfy employee tax obligations for vested stock-based awards were $(1.1) million for the three months ended September 30, 2026.
  • Shares repurchased to satisfy employee tax obligations for vested stock-based awards were $(5.0) million for the nine months ended September 30, 2026.

What drove it

  • Total third-quarter net sales increased 4.6%, while foreign currency translation had a negative impact of 0.6%, resulting in 5.2% organic net sales growth.
  • VWR Distribution & Services delivered 5.8% organic sales growth.
  • Bioscience & Medtech Products returned to organic growth, reporting 3.6% organic sales growth.
  • Management cited improving execution and stronger end markets as a foundation for sustained revenue growth.
  • Higher sales volume partially offset unfavorable product mix and higher SG&A expenses in VWR Distribution & Services.
  • Higher sales volume and commercial excellence offset higher SG&A expenses in Bioscience & Medtech Products.

Concerns

  • Adjusted EBITDA was $256.9 million, compared with $267.9 million in the prior-year period, and adjusted EBITDA margin was 15.1%, compared with 16.5%.
  • Adjusted Operating Income was $227.6 million, compared with $237.3 million in the prior-year period, and adjusted Operating Income margin was 13.4%, compared with 14.6%.
  • Adjusted net income was $146.4 million, compared with $151.1 million in the prior-year period.
  • VWR Distribution & Services adjusted Operating Income was $119.4 million, compared with $132.0 million, while its margin was 9.7%, compared with 11.2%.
  • Third-quarter operating cash flow was $195.1 million and free cash flow was $156.2 million, below $207.4 million and $171.7 million, respectively, in the prior-year period.
  • GAAP net leverage was 9.6x as of September 30, 2026.

What to watch

  • Delivery against updated fiscal 2026 organic revenue growth guidance of +0.75% to +1.25%.
  • Delivery against fiscal 2026 adjusted EBITDA margin guidance of 14.8% to 15.3%.
  • VWR Distribution & Services product mix, SG&A expenses and adjusted Operating Income margin.
  • Bioscience & Medtech Products' continuation of organic sales growth and commercial excellence.
  • Free cash flow delivery against updated fiscal 2026 guidance of $525M to $550M.
  • Progress in adjusted net leverage, which was 3.1x as of September 30, 2026.

Balance sheet and cash flow

  • Cash and cash equivalents were $464.3 million as of September 30, 2026, compared with $365.4 million as of December 31, 2025.
  • Total debt, gross, was $3,699.7 million as of September 30, 2026.
  • GAAP net leverage was 9.6x and adjusted net leverage was 3.1x as of September 30, 2026.
  • Net cash provided by operating activities was $195.1 million for the three months ended September 30, 2026, compared with $207.4 million in the prior-year period.
  • Free cash flow was $156.2 million for the three months ended September 30, 2026, compared with $171.7 million in the prior-year period.
  • Capital expenditures were $(38.9) million for the three months ended September 30, 2026, compared with $(35.7) million in the prior-year period.
  • Net cash provided by operating activities was $432.0 million for the nine months ended September 30, 2026, compared with $471.1 million in the prior-year period.
  • Free cash flow was $324.2 million for the nine months ended September 30, 2026, compared with $379.2 million in the prior-year period.
  • Capital expenditures were $(110.0) million for the nine months ended September 30, 2026, compared with $(93.3) million in the prior-year period.

Analysis

Avantor returned to reported and organic sales growth in the third quarter. Net sales were $1,698.3 million, up 4.6%, and organic net sales growth was 5.2% after a negative 0.6% foreign currency translation impact. VWR Distribution & Services posted $1,233.8 million of sales and 5.8% organic growth, while Bioscience & Medtech Products reported $464.5 million of sales and 3.6% organic growth. For the nine months ended September 30, 2026, net sales were $4,972.0 million, up 1.7%, while organic net sales growth was 0.3%.

Reported profitability improved sharply from the prior-year quarter, which included a $785.0 million non-cash goodwill impairment charge related to the former Distribution reporting unit. Third-quarter operating income was $139.5 million versus an operating loss of $(648.8) million, and net income was $203.4 million versus a net loss of $(711.8) million. The quarter also included a $105.4 million income tax benefit. Diluted GAAP EPS was $0.30, compared with $(1.04), while adjusted EPS was unchanged at $0.22.

Underlying profitability was lower year over year. Adjusted EBITDA was $256.9 million, with a 15.1% margin, compared with $267.9 million and 16.5%. Adjusted Operating Income was $227.6 million and its margin was 13.4%, compared with $237.3 million and 14.6%. VWR Distribution & Services adjusted Operating Income margin was 9.7%, down from 11.2%, due to unfavorable product mix and higher SG&A expenses, partially offset by higher sales volume. Bioscience & Medtech Products adjusted Operating Income margin was flat at 26.6%, as higher sales volume and commercial excellence were offset by higher SG&A expenses.

Cash generation remained positive but was lower than the prior-year period. Operating cash flow was $195.1 million and free cash flow was $156.2 million, compared with $207.4 million and $171.7 million, respectively. Total debt, gross, was $3,699.7 million and cash and cash equivalents were $464.3 million as of September 30, 2026. GAAP net leverage was 9.6x and adjusted net leverage was 3.1x.

Management raised fiscal 2026 organic revenue growth guidance to +0.75% to +1.25% from -0.5% to +0.5%, adjusted EPS guidance to $0.81 to $0.83 from $0.80 to $0.83, and free cash flow guidance to $525M to $550M from $500M to $550M. The adjusted EBITDA margin range remains 14.8% to 15.3%. The updated outlook calls for reported revenue growth of +1.5% to +2.0%, reflecting a +0.75% foreign exchange tailwind.

Management, verbatim

We are delighted to return to year-over-year growth in the third quarter. We are not done with our Revival journey yet, but this achievement reflects the dedication of our associates and the progress we are making to sharpen our strategic focus and improve execution. Third quarter results exceeded our expectations across revenue and adjusted EPS, and we generated robust free cash flow that allowed us to further strengthen our balance sheet.

Emmanuel Ligner, President and Chief Executive Officer

VWR Distribution & Services delivered another quarter of improving revenue performance, with organic growth accelerating to 5.8%, and Bioscience & Medtech Products returned to organic growth as expected. We believe that improving execution and stronger end markets provide a foundation for sustained revenue growth, and we remain focused on execution to build on our positive momentum.

Emmanuel Ligner, President and Chief Executive Officer

Not in the filing

stated, not guessed
  • GAAP gross margin for the three months ended September 30, 2026 and 2025 was not printed.
  • GAAP gross margin for the nine months ended September 30, 2026 and 2025 was not printed.
  • Prior-quarter comparisons for reported metrics were not provided.
  • Actual effective tax rate was not provided.
  • Fiscal 2026 gross margin guidance was not provided.
  • Fiscal 2026 operating expenses guidance was not provided.
  • Cash dividend information was not provided.
  • The previous outlook covered the full year 2026 only, so there is no guidance for this third quarter to compare against.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readAVTR · Second Quarter 2026 · ended June 30, 2026

Avantor Reports Second Quarter 2026 Results

→Mixed quarter

Net sales increased 0.5% and VWR Distribution & Services returned to positive organic growth, while consolidated organic sales declined 0.4%, net income fell to $38.1 million from $64.7 million, and Bioscience & Medtech Products sales declined 5.1%.

Revenue
$1.69B
increase of 0.5% y/y
VWR Distribution & Services
$1.24B
reported increase of 2.7%; sales increase of 1.7% on an organic basis y/y
EPS · non-GAAP
$0.21
Fiscal 2026 outlook
Organic revenue growth of -0.5% to +0.5%

Actuals vs. the company’s prior outlook

from its previous release
MetricGuidedReportedVerdict
Organic revenue growth-2.5% to -0.5%0.4% declinen/a
Adjusted EBITDA margin14.8% to 15.3%15.0%n/a
Adjusted EPS$0.77 to $0.83$0.21n/a
Free cash flow$500M to $550M$142.8 millionn/a

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net salesGAAP$1.69B–increase of 0.5%
Organic net sales growth (decline)non-GAAP0.4% decline–0.4% decline
Net incomeGAAP$38.1M––
Net income marginGAAP2.3%––
Adjusted net incomenon-GAAP$143.3M––
Operating incomeGAAP$121.8M––
Operating income marginGAAP7.2%––
Adjusted operating incomenon-GAAP$225.1M––
Adjusted operating income marginnon-GAAP13.3%––
Adjusted EBITDAnon-GAAP$254.3M––
Adjusted EBITDA marginnon-GAAP15.0%––
Diluted earnings per shareGAAP$0.06––
Adjusted diluted earnings per sharenon-GAAP$0.21––
Operating cash flowGAAP$178.2M––
Free cash flownon-GAAP$142.8M––

Segments

SegmentRevenueq/qy/y
VWR Distribution & ServicesForeign currency translation had a positive impact of 1.0%.$1.24B–reported increase of 2.7%; sales increase of 1.7% on an organic basis
Bioscience & Medtech ProductsForeign currency translation had a positive impact of 0.5%.$451.8M–reported decrease of 5.1%; 5.6% sales decline on an organic basis

Fiscal 2026 outlook

  • RevenueOrganic revenue growth of -0.5% to +0.5%
  • Tax rateAdjusted effective tax rate of approximately 22.5%
  • NoteReported revenue range is 0.0% to +1.0%, reflecting 0.5% foreign exchange tailwind
  • NoteAdjusted EBITDA margin of 14.8% to 15.3%
  • NoteAdjusted EPS of $0.80 to $0.83
  • NoteFree cash flow of $500M to $550M
  • NoteBlended EUR/USD exchange rate of 1.15
  • NoteNet interest expense is expected to decline modestly when compared to Fiscal 2025
  • NoteFully diluted share count of 677M shares

Capital returns

  • Repaid $112.1 million of debt.

What drove it

  • Foreign currency translation had a positive impact of 0.9% on consolidated net sales.
  • VWR Distribution & Services returned to positive organic revenue growth.
  • The Revival program is strengthening how the company serves customers, according to the Chief Executive Officer.
  • Bioscience & Medtech Products performed near the high end of expectations, according to the Chief Executive Officer.

Concerns

  • Consolidated net sales declined 0.4% on an organic basis.
  • Net income decreased to $38.1 million from $64.7 million in the second quarter of 2025.
  • Adjusted net income was $143.3 million compared to $161.2 million in the prior-year period.
  • Bioscience & Medtech Products reported a 5.1% sales decrease and a 5.6% organic sales decline.
  • Total debt, gross, was $3,715.4 million as of June 30, 2026.

What to watch

  • Execution against updated Fiscal 2026 organic revenue growth guidance of -0.5% to +0.5%.
  • Whether VWR Distribution & Services sustains its 1.7% organic sales increase.
  • Whether Bioscience & Medtech Products improves from its 5.6% organic sales decline.
  • Delivery of adjusted EBITDA margin of 14.8% to 15.3% and adjusted EPS of $0.80 to $0.83.
  • Free cash flow delivery of $500M to $550M, which excludes cash restructuring costs.
  • Progress on debt reduction following repayment of $112.1 million of debt.

Balance sheet and cash flow

  • Total debt, gross, was $3,715.4 million as of June 30, 2026.
  • Cash and cash equivalents were $306.8 million as of June 30, 2026.
  • GAAP net leverage was (5.9x) as of June 30, 2026.
  • Adjusted net leverage was 3.3x as of June 30, 2026.
  • Operating cash flow was $178.2 million for the three months ended June 30, 2026.
  • Free cash flow was $142.8 million for the three months ended June 30, 2026.

Analysis

Avantor reported $1,692.3 million of second-quarter net sales, up 0.5% year over year. Foreign currency translation contributed a positive 0.9%, leaving an organic net sales decline of 0.4%. The reported sales result therefore reflects modest growth supported by currency rather than consolidated underlying growth.

Segment trends were uneven. VWR Distribution & Services generated $1,240.5 million of sales, up 2.7% as reported and up 1.7% organically, marking a return to positive organic revenue growth. Bioscience & Medtech Products generated $451.8 million, down 5.1% as reported and down 5.6% organically. Both segments recorded lower adjusted operating income than in the comparable prior period: $126.4 million versus $141.6 million for VWR Distribution & Services and $117.6 million versus $131.4 million for Bioscience & Medtech Products.

Profitability and cash generation presented contrasting signals. GAAP net income decreased to $38.1 million from $64.7 million, and adjusted net income declined to $143.3 million from $161.2 million. Operating income was $121.8 million and adjusted operating income was $225.1 million. Adjusted EBITDA was $254.3 million, with a 15.0% adjusted EBITDA margin. Operating cash flow of $178.2 million and free cash flow of $142.8 million supported repayment of $112.1 million of debt.

The balance sheet remains a focus, with total debt, gross, of $3,715.4 million and cash and cash equivalents of $306.8 million as of June 30, 2026. The company reported GAAP net leverage of (5.9x) and adjusted net leverage of 3.3x. Management raised the lower ends of its Fiscal 2026 organic revenue growth range, from -2.5% to -0.5% to -0.5% to +0.5%, and adjusted EPS range, from $0.77 to $0.83 to $0.80 to $0.83. Adjusted EBITDA margin and free-cash-flow guidance were maintained.

The key reported operating issue is whether VWR Distribution & Services can sustain its organic improvement while Bioscience & Medtech Products recovers from its organic decline. The revised full-year outlook assumes a 0.5% foreign exchange tailwind and calls for reported revenue growth of 0.0% to +1.0%. Investors will also focus on the company’s ability to convert operations into the guided $500M to $550M of free cash flow while continuing to strengthen the balance sheet.

Management, verbatim

Our Revival program is strengthening how we serve our customers, leading to improved business performance

Emmanuel Ligner, President and Chief Executive Officer

Our second quarter results exceeded our expectations across several key financial metrics, and we generated robust free cash flow, which we used to repay $112.1 million of debt, reinforcing our commitment to strengthen our balance sheet. I’m delighted by the improved performance in our VWR Distribution and Services segment, which returned to positive organic revenue growth more quickly than we anticipated. Also, our Bioscience and Medtech Products segment performed near the high end of our expectations. We continue to focus on creating a better experience for our customers and delivering long-term value for our shareholders,

Emmanuel Ligner, President and Chief Executive Officer

Not in the filing

stated, not guessed
  • Gross profit and gross margin
  • Prior-year net sales amount
  • Prior-year operating income and operating income margin
  • Prior-year adjusted operating income and adjusted operating income margin
  • Prior-year adjusted EBITDA and adjusted EBITDA margin
  • Prior-year diluted GAAP EPS and adjusted EPS
  • Prior-year operating cash flow and free cash flow
  • Quarter-over-quarter comparisons for all reported metrics
  • Segment adjusted operating income margins for the comparable prior period
  • Capital expenditures
  • Free cash flow conversion
  • Share repurchases, dividends, and other shareholder capital returns
  • Net debt
  • Gross-margin guidance
  • Operating-expense guidance
  • Actual full-year Fiscal 2026 results for comparison with prior Fiscal 2026 guidance

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about AVTR earnings dates

When is Avantor's next earnings date?
AlphAI has no date for AVTR yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.